January 3, 2017 / 9:33 PM / 7 months ago

BRIEF-Agile Therapeutics announces positive top-line phase 3 results

1 Min Read

Jan 4 (Reuters) - Agile Therapeutics Inc

* Agile Therapeutics announces positive top-line phase 3 results

* Agile Therapeutics Inc - company plans to resubmit nda in first half of 2017

* Agile Therapeutics-secure was conducted to address issues raised by u.s. Food and drug administration in its 2013 complete response letter to company

* Says resubmission of twirla new drug application expected to address fda's complete response letter

* Agile Therapeutics Inc - believes its cash and cash equivalents will be sufficient to meet its operating requirements through end of 2017

* Agile Therapeutics Inc - twirla was generally well tolerated and had an overall favorable safety profile

* Agile Therapeutics - plans to prepare its response to fda's crl, which will also include information relating to manufacture of twirla requested by FDA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below